ACHC vs. PCVX, ELAN, ENSG, XRAY, HQY, CYTK, EXEL, JAZZ, GMED, and IONS
Should you be buying Acadia Healthcare stock or one of its competitors? The main competitors of Acadia Healthcare include Vaxcyte (PCVX), Elanco Animal Health (ELAN), The Ensign Group (ENSG), DENTSPLY SIRONA (XRAY), HealthEquity (HQY), Cytokinetics (CYTK), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Globus Medical (GMED), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Acadia Healthcare (NASDAQ:ACHC) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Acadia Healthcare received 521 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 67.39% of users gave Vaxcyte an outperform vote while only 66.83% of users gave Acadia Healthcare an outperform vote.
In the previous week, Acadia Healthcare and Acadia Healthcare both had 12 articles in the media. Vaxcyte's average media sentiment score of 0.74 beat Acadia Healthcare's score of 0.60 indicating that Vaxcyte is being referred to more favorably in the news media.
96.8% of Vaxcyte shares are owned by institutional investors. 2.8% of Acadia Healthcare shares are owned by company insiders. Comparatively, 3.6% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Acadia Healthcare presently has a consensus target price of $92.00, indicating a potential upside of 25.02%. Vaxcyte has a consensus target price of $78.50, indicating a potential upside of 29.28%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts clearly believe Vaxcyte is more favorable than Acadia Healthcare.
Acadia Healthcare has higher revenue and earnings than Vaxcyte. Acadia Healthcare is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.
Acadia Healthcare has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Vaxcyte has a net margin of 0.00% compared to Acadia Healthcare's net margin of -0.74%. Acadia Healthcare's return on equity of 11.21% beat Vaxcyte's return on equity.
Summary
Acadia Healthcare and Vaxcyte tied by winning 8 of the 16 factors compared between the two stocks.
Get Acadia Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acadia Healthcare Competitors List
Related Companies and Tools
